Navigation With X3 vs Non-Navigation With X3 Study
Comparison X3 Study Between Navi-THA and Non-navi-THA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Osaka
-
Osaka City, Osaka, Japan, 591-8025
- Osaka Rosai Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient who is a candidate for a primary total hip arthroplasty (THA) with cementless acetabular and femoral components.
- Patient who has a diagnosis of degenerative joint disease and no bacterial infectious disease.
- Patient who is age 20 or over.
- Patient who signed an Institutional Review Board (IRB)-approved, study specific Informed Patient Consent Form.
- Patient who is willing to and able to comply with postoperative scheduled evaluations.
Exclusion Criteria:
- Patient who has a bacterial infectious disease or has a high risk of a bacterial infection.
- Patient who requires revision surgery of a previously implanted total hip arthroplasty.
- Patient who is morbidly obese, defined as having a Body Mass Index (BMI) > 45.
- Patient who is or may be pregnant female.
- Patient who has neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
- Patient with diagnosed systemic disease (i.e. Paget's disease, renal osteodystrophy).
- Patient who is immunologically suppressed or receiving chronic steroids.
- Patient who is judged ineligible with specific reason by primary doctor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: With Navigation system
Large diameter head with Trident X3 insert with Navigation system
|
|
|
Other: Without Navigation system
Large diameter head with Trident X3 insert with conventional instrumentation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Range of motion (ROM) during surgery
Time Frame: intraoperative
|
intraoperative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measuring accuracy of the ROM during surgery
Time Frame: Intraoperative
|
Measurement ROM precision of intraoperative
|
Intraoperative
|
|
implantation accuracy
Time Frame: Intraoperative
|
Measurement of the degree of stem anteversion, cup anteversion and cup abduction
|
Intraoperative
|
|
Postoperative dislocation
Time Frame: From intraoperative to 1yr
|
From intraoperative to 1yr
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yasuyuki Inatsugu, Stryker Japan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SJCR-OR-1101v2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.